TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

Summary

This is a Phase 1 pharmacokinetic (PK) study in healthy participants to assess the plasma pharmacokinetics, safety, and tolerability of a single inhaled dose of nezulcitinib (TD-0903) with supplemental oxygenation.

Timeline

Start

2021-10-13

Primary completion

2021-11-24

Completion

2021-11-24

Drugs

Indications